Cargando…

Structural basis for differential p19 targeting by IL-23 biologics

BACKGROUND: IL-23 is central to the pathogenesis of psoriasis, and is structurally comprised of p19 and p40 subunits. “Targeted” IL-23 inhibitors risankizumab, tildrakizumab, and guselkumab differ mechanistically from ustekinumab because they bind p19, whereas ustekinumab binds p40; however, a knowl...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniele, Stefano G., Eldirany, Sherif A., Ho, Minh, Bunick, Christopher G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029002/
https://www.ncbi.nlm.nih.gov/pubmed/36945513
http://dx.doi.org/10.1101/2023.03.09.531913

Ejemplares similares